Adenosine has been shown to inhibit immunoreactive gastrin (IRG) release and to stimulate somatostatin-like immunoreactivity (SLI) release by activating adenosine A 1 and A 2A receptors, respectively. Since the synthesis and release of gastrin and somatostatin are regulated by the acid secretory state of the stomach, the effect of achlorhydria on A 1 and A 2A receptor gene expression and function was examined. Omeprazole-induced achlorhydria was shown to suppress A 1 and A 2A receptor gene expression in the antrum and corporeal mucosa, but not in the corporeal muscle. Omeprazole treatment produced reciprocal changes in A 1 receptor and gastrin gene expression, and parallel changes in A 2A receptor and somatostatin gene expression. The localization of A 1 and A 2A receptors on gastrinsecreting G-cells and somatostatin-secreting D-cells, respectively, suggests that changes in adenosine receptor expression may modulate the synthesis and release of gastrin and somatostatin. Thus, the effect of omeprazole on adenosine receptormediated changes in IRG and SLI release was also examined in the vascularly perfused rat stomach. After omeprazole treatment, the A 1 receptor-mediated inhibition of IRG and SLI release induced by N 6 -cyclopentyladenosine (A 1 receptor-selective agonist) was not altered, but the A 2A receptor-mediated augmentation of SLI release induced by 2-p-(2-carboxyethyl-)phenethylamino-5Ј-N-ethylcarboxamidoadenosine (A 2A -selective agonist) was significantly attenuated. These findings agree well with the corresponding omeprazole-induced decrease in antral A 2A receptor mRNA expression. Overall, the present study suggests that adenosine receptor gene expression and function may be altered by omeprazole treatment. Acid-dependent changes in adenosine receptor expression may represent a novel purinergic regulatory feedback mechanism in controlling gastric acid secretion.
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Adenosine has been demonstrated to protect the stomach against stress-induced ulcer formation (Geiger and Glavin, 1985; Westerberg and Geiger, 1987) , to inhibit gastric acid secretion (Gerber et al., 1985; Heldsinger et al., 1986; Scarpignato et al., 1987) , and to modulate the release of gastric regulatory peptides (Kwok et al., 1990) . Unlike in other species (Gerber et al., 1985; Heldsinger et al., 1986) , adenosine does not alter gastric acid secretion in the rat by acting directly on the acid-secreting parietal cells (Puurunen et al., 1987) . Instead, our laboratory has shown that in the isolated vascularly perfused rat stomach, the exogenous administration of adenosine suppressed and augmented the release of immunoreactive gastrin (IRG) and somatostatinlike immunoreactivity (SLI), respectively (Kwok et al., 1990) . Thus, in these animals, adenosine may exert its inhibitory action on acid secretion indirectly by regulating the release of the gastric acid secretagogue, gastrin, and the acid inhibitor, somatostatin. In addition, adenosine deaminase, a metabolic enzyme of adenosine, has been shown to enhance basal and carbachol-stimulated IRG release in rat antral mucosal fragments (Harty and Franklin, 1984) and to inhibit basal gastric SLI release , whereas dipyridamole, an adenosine uptake blocker, and erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride, an inhibitor of adenosine deaminase, were shown to enhance basal SLI release in the perfused rat stomach (Kwok et al., 1990; . These findings suggest that endogenous adenosine may play a role in controlling the release of gastrin and somatostatin, and consequently, gastric acid.
Adenosine elicits its actions by activating specific G-pro-tein-coupled receptors that are classified into the A 1 , A 2A , A 2B , and A 3 receptor subtypes (Fredholm et al., 2001) . The inhibitory and stimulatory effects of adenosine on IRG and SLI release are likely mediated by the activation of A 1 and A 2A receptors, respectively (Schepp et al., 1990; Yip et al., 2004b) . Furthermore, the basal release of SLI is likely to be under the control of the A 2A receptors since ZM 241385 (A 2A receptor-selective antagonist) was shown to suppress basal SLI release . The A 1 and A 2A receptors were shown to be expressed throughout the antral and corporeal mucosa, and in the enteric plexi Yip et al., 2004b Our laboratory has demonstrated that fasting, a condition that increases gastric acidity (Matsumoto et al., 1989) , upregulated gastric A 1 and A 2A receptor gene expression and altered gastrin and somatostatin gene expression (Yip and Kwok, 2002) . The proton pump inhibitor, omeprazole, has also been demonstrated to alter gastrin and somatostatin gene expression (Brand and Stone, 1988; Wu et al., 1990; Sandvik et al., 1995) . However, it is unclear whether omeprazole-induced achlorhydria also alters adenosine receptor gene expression. The objective of the present study was to examine whether short-term omeprazole treatment alters adenosine A 1 and A 2A receptor gene expression and function. The gene expression of gastrin and somatostatin was also measured since changes in adenosine receptor expression may be associated with changes in gastrin and somatostatin gene expression and release. To examine whether omeprazole-induced changes in adenosine receptor gene expression also result in corresponding changes in adenosine receptormediated SLI and IRG release, the effect of selective adenosine agonists on SLI and IRG release were also studied following omeprazole treatment.
Materials and Methods
Animals were treated in accordance with the guidelines of the University of British Columbia Committee on Animal Care.
Omeprazole Treatment
Male Wistar rats (250 -270 g) housed in light-and temperaturecontrolled rooms with free access to food and water were used. As suggested by the manufacturer, omeprazole (50 mol/ml; AstraZeneca, Mölndal, Sweden) was thoroughly dispersed in 0.25% Methocel (Dow Corning, Midland, MI) containing 2 mg/ml NaHCO 3 (pH 9.0) using the Tissumizer tissue homogenizer (Tekmar-Dohrmann, Mason, OH). The drug was aliquoted, frozen, and stored at Ϫ20°C. To prevent drug degradation due to repeated freezing and thawing, a new aliquot of drug was thawed overnight at 4°C and brought to room temperature before administration. Test groups were treated by gavage with a dose of 400 mol/kg omeprazole once daily between 9:00 and 10:00 AM for either 1 or 3 days. These regimens were selected since gastric acid secretion is decreased by up to 80% after 1 day of treatment with 400 mol/kg omeprazole (Larsson et al., 1988; Lee et al., 1992) , and steady-state inhibition is achieved after 3 days of treatment at this dose (Carlsson et al., 1986 ). Rats were not treated for more than 3 days since G-cell and/or D-cell densities are altered after 4 days (Bolkent and Yilmazer, 1997) and 5 days (Pawlikowski et al., 1992) of treatment. Control groups were treated similarly with the vehicle. Animals were anesthetized with an i.p. injection of 60 mg/kg sodium pentobarbital (Somnotol; MTC Pharmaceuticals, Cambridge, ON, Canada), 24 h after the last treatment, and tissue extraction occurred between 10:00 and 11:00 AM.
Quantification of Adenosine A 1 and A 2A Receptor and Gastric Peptide Gene Expression
The quantitative real-time RT-PCR developed to measure A 1 and A 2A receptor gene expression has previously been described Yip et al., 2004b) . Two-step real-time RT-PCR assays were used to quantify the gene expression of adenosine A 1 and A 2A receptors, gastrin, and somatostatin in various gastric regions following omeprazole treatment. Primers and probes were designed using the Primer Express Sequence Design software program (v. 1.0; Applied Biosystems, Foster City, CA). The reporter dye, 6-carboxyfluorescein, and the quencher dye, 6-carboxytetramethylrhodamine, were linked to the 5Ј and 3Ј ends of the probes, respectively. The sequences of the forward primers, reverse primers, and probes used are listed in Table 1 . The primers and probes were synthesized by the Nucleic Acid Protein Services Unit (University of British Columbia) and Synthegen, LLC (Houston, TX), respectively. A 1 and A 2A Receptor Gene Expression. RNA transcripts expressing the entire coding region of the A 1 and A 2A receptors were used as the standards for real-time RT-PCR. The standards were synthesized from plasmids containing the A 1 or A 2A receptor transcript by in vitro transcription using the Riboprobe in vitro transcription kit and T7 RNA polymerase (Promega, Madison, WI), as previously described Yip et al., 2004b) . Adenosine receptor RNA standards were treated with DNase I (Amersham Biosciences Inc., Piscataway, NJ) and purified. Standard concentrations were determined using the RiboGreen Reagent Quantitation kit (Molecular Probes, Eugene, OR), the FL600 Microplate Fluorescence reader (Bio-Tek Instruments, Winooski, VT), and the KC4 Kineticalc Software (version 2.6; Bio-Tek Instruments), according to the manufacturer's instructions. RNA standards were serially diluted to 1 ϫ 10 3 to 1 ϫ 10 12 copies/l in RNase-free water, aliquoted, stored at Ϫ80°C, and thawed only once before use.
Gastrin and Somatostatin Gene Expression. Relative gastrin and somatostatin gene expression levels were measured using a sample of rat antrum total RNA to produce the standards for the standard curve. Antral total RNA (1 g) was reverse transcribed into 10 l of cDNA using SuperScript II RNase H-Reverse Transcriptase. This sample was designated as the 100 ng/l sample since 100 ng of total RNA was reverse transcribed to produce 1 l of cDNA. This sample was then serially diluted to various concentrations (0.1 ng/l to 100 ng/l) to produce a relative standard curve.
Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) and 18S rRNA Gene Expression. The expression of GAPDH mRNA and 18S rRNA was measured using the Rodent GAPDH Control Reagents Kit (Applied Biosystems) and the TaqMan ribosomal RNA Control Reagents Kit (Applied Biosystems), respectively, according to the protocol described in the PE Applied Biosystems User Bulletin 2. A relative standard curve was constructed using the Rodent Control RNA Standard (50 ng/l) provided with the kit. Rodent Control RNA (100 ng) was reverse transcribed into 10 l of cDNA using SuperScript II RNase H-Reverse Transcriptase. This sample was designated as the 10 ng/l sample since 10 ng of Rodent Control RNA was used to produce 1 l of cDNA. The 10 ng/l sample was diluted to 7.5, 5, 2.5, 1, 0.5, and 0.1 ng/l, and these samples were used to construct the relative standard curve for the real-time RT-PCR assay. The 18S rRNA and GAPDH real-time RT-PCR assays were performed according to the manufacturer's instruction.
Tissue and Total RNA Extraction
The corporeal mucosa, corporeal muscle, and antrum were dissected out. These regions were examined since the corporeal mucosa contains somatostatin-secreting D-cells, the corporeal muscle contains somatostatin-releasing nerve fibers, and the antrum contains D-cells, gastrin-secreting G-cells, and somatostatin-releasing nerve fibers. Care was taken to avoid inclusion of tissue at the antro-corpus border. Since the antrum is a relatively small tissue, total RNA was extracted from the whole antrum to ensure consistency among samples. The corpus was separated into the corporeal mucosa and muscle. The whole corpus tissue was rinsed in ice-cold saline, and the mucosa was removed from the corpus with gentle scraping using a sterile glass slide. The mucosa was then rinsed off the slide using TRIzol reagent (Invitrogen, Carlsbad, CA), and total RNA was extracted immediately using the same reagent. The corporeal muscle and antrum were flash frozen in liquid nitrogen and stored at Ϫ80°C until RNA extraction. Total RNA was extracted from all tissues using TRIzol reagent, according to the manufacturer's instructions, and concentrations were determined using the RiboGreen Quantitation Kit (Molecular Probes). Total RNA samples were treated with DNase I to remove any residual DNA contamination that may remain in samples after total RNA extraction. DNase I treatment was performed at room temperature in 1ϫ first strand buffer [50 mM Tris-HCl (pH 8.3 at 25°C), 75 mM KCl, 3 mM MgCl 2 ] containing 1 U DNase I/g total RNA. The reaction was allowed to proceed for 15 min, before 1 l of 25 mM EDTA was added to stop the reaction. Samples were then incubated for an additional 10 min at 65°C.
Two Step Real-Time RT-PCR
Reverse Transcription. DNase I-treated tissue RNA (1 g) was reverse transcribed in a total volume of 10 l containing 200 ng of random hexamers, 20 U of RNAguard RNase inhibitor (Amersham Biosciences Inc.), 1ϫ first strand buffer, 10 mM dithiothreitol, 0.5 mM deoxynucleoside-5Ј-triphosphate mix, and 100 U of SuperScript II RNase H-Reverse Transcriptase. At least six concentrations of each standard and a sample containing DNase I-treated RNase-free water in place of the template (negative control) were reverse transcribed simultaneously. The reverse transcribed RNA standards were used to construct the standard curve for the real-time RT-PCR assay.
PCR. Each assay consisted of at least six standard curve samples, a negative control sample, and unknown samples. All reactions were performed in triplicate. The PCR reaction mixture (25 l) consisted of 1ϫ TaqMan buffer A; 200 M concentrations, each, of dATP, dCTP, and dGTP; 400 M dUTP; 0.01 U/l AmpErase uracil-Nglycosylase; and 0.025 U/l AmpliTaq Gold DNA polymerase from the TaqMan PCR Core Kit (Applied Biosystems). Reaction mixtures also contained 0.5 l of tissue cDNA, standard cDNA, or negative control; 100 nM probe; 100 nM (A 2A receptor, gastrin and somatostatin assay) or 300 nM (A 1 assay) concentrations, each, of the forward and reverse primers; and 7.5 mM MgCl 2 (A 1 receptor, gastrin, and somatostatin assay) or 4.5 mM MgCl 2 (A 2A receptor assay). The reaction was performed using the ABI Prism 7700 Sequence Detector (Applied Biosystems) with the following cycling parameters: 2-min hold at 50°C for uracil-N-glycosylase incubation, 10-min hold at 95°C for AmpliTaq Gold activation, followed by 40 cycles of amplification consisting of a 15-s denaturation step at 95°C and 1-min anneal/ extend period at 60°C.
Data Collection and Analysis. Data were collected during each PCR cycle and analyzed using the Sequence Detection Software (v. 1.6.3; Applied Biosystems). An amplification plot showing normalized reporter emissions versus cycle number was generated. The threshold cycle (C T ), the cycle during which an increase in fluorescence is associated with exponential growth, was determined by the software using the fluorescence emitted during the first 15 cycles. A standard curve of C T versus log (initial standard concentrations) was then generated. The initial concentration of each unknown sample was determined by interpolation using the C T value determined by the assay. The correlation coefficient of each standard curve was Ͼ0.95, and the C T of the negative control exceeded 40 cycles in every assay, indicating the absence of DNA contamination. To compare gene expression levels between the test and control animals, measurements were first normalized with the gene expression of the endogenous control (18S rRNA). This was performed according to the procedures described in the PE Applied Biosystems User Bulletin 2. The adenosine A 1 receptor, A 2A receptor, gastrin, or somatostatin gene expression level of each individual sample was divided by the 18S rRNA level to obtain a normalized value of measurement. The mean Ϯ S.E.M. of this normalized value was calculated for control and omeprazole-treated groups. The mean of each control group was expressed as 100%, and gene expression levels of the omeprazoletreated groups were expressed as a percentage of the control. Statistical significance was determined using the two-tailed unpaired Student's t test and was performed using GraphPad Prism (v. 3.0; GraphPad Inc., San Diego, CA); P Յ 0.05 was considered significant.
Stomach Perfusion
Rats were housed in light-and temperature-controlled rooms with free access to food and water. Omeprazole-treated animals were deprived of food for 12 to 14 h but had free access to water before stomach perfusion. Rats were anesthetized with Somnotol (60 mg/ kg). The procedures used to prepare the stomach for perfusion have previously been described (Kwok et al., 1990) . Following the exposure of the stomach through an abdominal midline incision, the superior mesenteric artery and vasculatures supplying the left and right adrenal glands and kidneys were occluded or cut between double ligatures. The pancreas and spleen were then dissected along the greater curvature of the stomach, while preserving the right gastroepiploic artery. A cannula was secured into the gastroduodenal junction for drainage of any gastric contents. The spleen, pancreas, and small and large intestines were then dissected out. Arterial perfusion was achieved through a cannula inserted into the aorta with the tip lying adjacent to the celiac artery. An injection of 2 ml of saline containing 600 U of heparin (Sigma-Aldrich, St. Louis, MO) was introduced into the gastric circulation through this arterial cannula, followed by perfusate. Venous effluent was collected via the portal vein cannula. The preparation was equilibrated for 30 min before 5-min samples were collected into ice-cold scintillation vials containing 0.3 ml of Trasylol (aprotinin; 10,000 KIU/ml; Miles Laboratories, Etobicoke, ON, Canada). Aliquots (0.5 ml) of samples were immediately transferred into ice-cold test-tubes containing 0.05 ml of aprotinin and stored at Ϫ20°C until assayed. The stomach was perfused at a rate of 3 ml/min using a peristaltic pump (Cole-Parmer Instrument Co., Vernon Hills, IL). The perfusate was composed of Krebs' solution (120 mM NaCl, 4.4 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 ⅐7H 2 O, 1.5 mM KH 2 PO 4 , 25 mM NaHCO 3 , and 5.1 mM dextrose) containing 0.2% bovine serum albumin (RIA grade; SigmaAldrich) and 3% dextran (Clinical grade; Sigma-Aldrich). The perfusate was continuously gassed with a mixture of 95% O 2 and 5% CO 2 to maintain a pH of 7.4. Both the perfusate and the preparation were kept at 37°C by thermostatically controlled heating units throughout the experiment. Drugs were introduced into the perfusate via side-arm infusion at a rate calculated to give the final perfusion concentrations. N 6 -Cyclopentyladenosine (CPA) and 2-p-(2-carboxyethyl)phenethylamino-5Ј-N-ethylcarboxamidoadenosine HCl (CGS 21680) were purchased from Sigma-Aldrich. Drugs were first dissolved in a small volume of DMSO (BDH, Toronto, ON, Canada) and subsequently diluted with saline or perfusate to 0.03 or 0.5% DMSO before perfusing into the stomach. At these concentrations, DMSO did not alter basal IRG or SLI release. The perfusion concentrations of the A 1 receptor agonist, CPA, and A 2A receptor agonist, CGS 21680, were 0.1 or 1 M. The lower concentration (0.1 M) was selected to approximate the EC 50 of CPA (0.067 M with a 95% confidence interval between 0.014 and 0.325 M) (Yip et al., 2004b) and CGS 21680 (0.06 M with a 95% confidence interval between 0.02 and 0.17 M) in inhibiting and stimulating IRG and SLI release, respectively. The higher concentration (1 M) was also examined since CPA and CGS 21680 elicited their maximal effects at this concentration.
Measurement of Gastric Peptides and Data Analysis
The specific RIA used for the measurement of IRG (Jaffe and Walsh, 1978; Fujimiya and Kwok, 1997) and SLI (McIntosh et al., 1987; Kwok et al., 1990) have previously been described. The gastrin antibody (PM1) used to measure IRG was kindly provided by Dr. R. Pederson (Department of Physiology, University of British Columbia). The inter-and intra-assay variation was less than 6 and 4%, respectively. The monoclonal antibody, SOMA-3 (Medical Research Council-Regulatory Peptide Group, University of British Columbia), was used to measure SLI. The inter-and intra-assay variation of the RIA was less than 12 and 8%, respectively. The drugs used in the present study did not cross-react with these antibodies.
Although the basal release rate of IRG and SLI release varied among animals, previous experiments have demonstrated that basal IRG (Pederson et al., 1984; Kwok et al., 1990) and SLI release (Kwok et al., 1990) were maintained in the perfused stomach. Therefore, results were expressed as mean Ϯ S.E.M. of IRG or SLI release (percentage), which was calculated as follows: [release (pg/min) during a 5-min period Ϭ release (pg/min) during period 1] ϫ 100. Results were also expressed as percentage inhibition of IRG release, which was calculated as follows: [mean basal IRG release (periods 1-3) Ϫ mean IRG release in the presence of drug (periods 4 -7)] pg/min Ϭ [mean basal IRG release (periods 1-3)] pg/min ϫ 100. The percentage change of SLI release was calculated as follows: (mean SLI release in the presence of drug Ϫ mean basal SLI release) pg/min Ϭ (mean basal SLI release) pg/min ϫ 100. Statistical significance (P Ͻ 0.05) was determined using one-way ANOVA followed by Dunnett's multiple comparison test, and the paired or unpaired Student's t test when appropriate.
Results
Effect of Omeprazole Treatment on 18S rRNA and GAPDH Gene Expression. Omeprazole treatment was found to alter GAPDH mRNA levels in various gastric regions. The gene expression of GAPDH in the corporeal mucosa was significantly decreased to 65 Ϯ 5% of control levels after 3 days of omeprazole treatment. In the corporeal muscle, the GAPDH mRNA level was significantly increased to 130 Ϯ 9% after 1 day of treatment (Fig. 1A) . In all gastric regions examined, 18S rRNA levels were not altered by 1 or 3 days of omeprazole treatment (Fig. 1B) . Since omeprazole treatment did not alter 18S rRNA levels, this gene was used as the endogenous control for the subsequent quantification of gastric A 1 receptor, A 2A receptor, somatostatin, and gastrin gene expression using real-time RT-PCR.
Effect of Omeprazole Treatment on Adenosine A 1 and A 2A Receptor Gene Expression. Figure 2A shows that antral adenosine A 1 receptor gene expression was significantly reduced to 66 Ϯ 12% and 47 Ϯ 8% of control levels after 1 and 3 days of omeprazole treatment, respectively. In the corporeal mucosa, A 1 receptor gene expression was significantly decreased to 62 Ϯ 6% of control levels after 1 day of treatment, but changes were not apparent after 3 days of treatment. The gene expression of the A 2A receptor was significantly reduced in the antrum to 57 Ϯ 7% of control levels after 3 days of treatment (Fig. 2B) . A 2A receptor gene expression was also decreased in the corporeal mucosa, to 67 Ϯ 14% of control levels, after 1 day of treatment. However, changes were not detected in this tissue after 3 days of treatment. In the corporeal muscle, neither A 1 receptor nor A 2A receptor gene expression was altered by omeprazole treatment.
Effect of Omeprazole Treatment on Gastrin and Somatostatin Gene Expression. Antral gastrin gene expression was significantly increased to 201 Ϯ 18% and 268 Ϯ 42% of controls after 1 and 3 days of omeprazole treatment, respectively (Fig. 3A) . In contrast, after 1 and 3 days of omeprazole treatment, antral somatostatin gene expression was significantly reduced to 71 Ϯ 6% and 58 Ϯ 4% of controls, respectively. The somatostatin gene expression in the corporeal mucosa was also reduced to 54 Ϯ 13% and 54 Ϯ 10% of control levels after 1 and 3 days of treatment, respectively (Fig. 3B ). In the corporeal muscle, a significant decrease (45 Ϯ 6%) in somatostatin gene expression was observed following 3 days of omeprazole treatment.
Effect of Omeprazole on CPA-Induced Changes in IRG Release. Previous studies have shown that adenosine A 1 receptors are involved in the inhibition of IRG release. Thus, the effect of omeprazole treatment on CPA (A 1 -selective agonist)-induced changes in IRG release was examined. Figure 4A shows the effect of 0.1 M CPA on IRG release in animals after 1-day treatment with omeprazole. Basal IRG release during periods 1 to 3 in control (222 Ϯ 46 to 238 Ϯ 52 Previous studies have demonstrated that the administration of 0.1 M CPA significantly inhibited gastric SLI release, whereas the administration of 1 M CPA significantly stimulated SLI release . These findings were also observed in the current study (Figs. 8 and 9 ). Figure 8A shows the effect of 0.1 M CPA on SLI release after 1 day of omeprazole treatment. Basal SLI release did not differ significantly between control (227 Ϯ 33 to 234 Ϯ 30 pg/min) and treated (194 Ϯ 27 to 197 Ϯ 21 pg/min) animals. The administration of 0.1 M CPA significantly reduced SLI release. However, this inhibitory response did not differ between control and 1-day omeprazole-treated animals. Figure  8B shows the effect of 1 M CPA on SLI release after 3 days of omeprazole treatment. Basal SLI release was comparable between control (158 Ϯ 33 to 165 Ϯ 37 pg/min) and treated (134 Ϯ 26 and 138 Ϯ 30 pg/min) animals. The administration of CPA (1 M) significantly increased SLI release. This stimulatory response was shown to be attenuated after 3 days of omeprazole treatment. The effect of omeprazole treatment on CPA-induced changes in SLI release is summarized in Fig. 9 . The inhibition of SLI release induced by 0.1 M CPA was not altered by either 1 or 3 days of omeprazole treatment. How- Fig. 1 . Effect of omeprazole treatment on gastric housekeeping gene expression. GAPDH mRNA (A) and 18S rRNA (B) levels were measured in rats treated with vehicle or omeprazole (OM) for 1 or 3 days; n Ն7. Results are expressed as a percentage of the control as described under Materials and Methods; ૺ, P Ͻ 0.05. ever, 3 days of treatment did significantly attenuate the stimulatory effect of 1 M CPA on SLI release (Fig. 9) .
Discussion
In the present study, the gene expression of GAPDH, a commonly used housekeeping gene, was shown to be significantly increased in the corporeal muscle and decreased in the corporeal mucosa after 1 and 3 days of omeprazole treatment, respectively. These findings are consistent with another study demonstrating increased GAPDH mRNA levels in the rat corpus after omeprazole treatment (Sandvik et al., 1995) . In contrast, 18S rRNA gene expression was not altered by omeprazole treatment. Therefore, 18S rRNA was used as the endogenous control for the measurement of A 1 receptor, A 2A receptor, somatostatin, and gastrin gene expression. Results demonstrate that both gastrin and somatostatin mRNA levels were altered by omeprazole treatment. The observation that 1 and 3 days of omeprazole treatment led to increased gastrin mRNA levels agrees well with other studies showing increased expression after 4 and 14 days of omeprazole treatment (Wu et al., 1990; Dockray et al., 1991) . The present study also demonstrates decreased antral somatostatin gene expression after 1 and 3 days of treatment, which also agrees well with the findings of other investigators (Brand and Stone, 1988; Wu et al., 1990; Sandvik et al., 1995) . Similar to previous studies (Tari et al., 1991; Sandvik et al., 1995) , the present study also demonstrates reduced somatostatin mRNA expression in the corporeal mucosa and muscle following omeprazole treatment.
We have previously demonstrated that adenosine may regulate gastric acid secretion by suppressing IRG and stimulating SLI release via activation of A 1 and A 2A receptors, respectively Yip et al., 2004b) . The present study suggests that the gene expression and function of these receptors may be regulated by changes in the acid-secretory state of the stomach. Omeprazole treatment inhibited A 1 receptor gene expression in the antrum (1-and 3-day treatment) and corporeal mucosa (1-day treatment), and A 2A receptor gene expression in the antrum (3-day treatment) and corporeal mucosa (1-day treatment). The precise cellular localization of both receptors has been examined in these tissues Yip et al., 2004b) . A 1 receptors were shown to be expressed on D-cells and G-cells, whereas A 2A receptors are expressed on D-cells. Thus, it is plausible that omeprazole-induced changes in adenosine receptor gene expression may occur in the mucosal G-cells and/or D-cells of the corpus and antrum. Both of these adenosine receptors have also been localized in the enteric plexi. However, changes in A 1 and A 2A receptor gene expression were not observed in the corporeal muscle after omeprazole treatment, suggesting that adenosine receptor gene expression in the corporeal enteric plexi was unlikely altered by omeprazole treatment.
Conditions that increase intracellular acidity, such as hypoxia or ischemia, have previously been shown to up-regulate Omeprazole on Gastric A 1 and A 2A Receptors Fig. 3 . Effect of omeprazole treatment on gastric peptide gene expression. Gastrin (A) and somatostatin (B) mRNA levels were measured in rats treated with omeprazole (OM) for 1 or 3 days; n Ն7. Results are expressed as a percentage of the control, as described under Materials and Methods; ૺ, P Ͻ 0.05; ૺૺ, P Ͻ 0.01; ૺૺૺ, P Ͻ 0.001. Fig. 4 . Effect of CPA on gastric IRG release in 1-day (A) and 3-day (B) omeprazole (OM)-treated animals. Results are expressed as IRG release (percentage) as described under Materials and Methods. Each column represents the mean Ϯ S.E.M. ૺ, P Ͻ 0.05, and ૺૺૺ, P Ͻ 0.001 when compared with period 3 using repeated measures ANOVA followed by Dunnett's multiple comparison test (n Ն5). The IRG release during each 5-min period was not significantly different between omeprazole-treated and control animals when compared using the Student's unpaired t test.
A 1 and A 2A receptor gene expression in DDT1-MF2 cells (Nie et al., 1998) and PC12 cells (Kobayashi and Millhorn, 1999) , respectively. In addition, fasting, which increases gastric acidity (Matsumoto et al., 1989) , has been shown to upregulate both gastric A 1 and A 2A receptor mRNA levels (Yip and Kwok, 2002) . In the present study, adenosine receptor gene expression was reduced following omeprazole-induced achlorhydria. This observation fits the proposal that adenosine receptor gene expression may respond to changes in acidity.
When omeprazole-induced changes in adenosine receptor and gastric regulatory peptide gene expression were compared, a reciprocal relationship was observed between changes in A 1 receptor and gastrin gene expression. Although a clear relationship between A 2A receptor and somatostatin gene expression was not apparent, the expression of both genes was reduced in gastric tissues after various lengths of omeprazole treatment. Omeprazole-induced achlorhydria may decrease adenosine receptor expression and subsequently alter the synthesis and release of gastrin and somatostatin. Expression of both gastrin and somatostatin genes is enhanced by cAMP formation (Shiotani and Merchant, 1995; Montminy et al., 1996) . Activation of A 1 and A 2A receptors inhibits and stimulates cAMP formation, respectively (Ralevic and Burnstock, 1998) . Thus, activation of adenosine receptors may alter cAMP levels to regulate gastrin and somatostatin gene expression. Studies have shown that A 2A receptor stimulation can induce the expression of genes regulated by cAMP (Chae and Kim, 1997; Ravid et al., 1999) . Therefore, a reduction in A 2A receptor gene expression may lead to a subsequent decrease in somatostatin gene expression.
Although the possible regulatory mechanism(s) involved in the modulation of adenosine receptor gene expression by omeprazole was not examined in the present study, the expression of the A 1 and A 2A receptor gene may be regulated by changes in gastric acidity, as suggested for gastrin and somatostatin gene expression. Omeprazole, however, has also been shown to induce the expression of various genes, through the activation of specific intracellular signaling pathways (Backlund et al., 1997; Kikuchi and Hossain, 1999) . Therefore, the direct regulation of A 1 and A 2A receptor gene expression by omeprazole cannot be ruled out.
Omeprazole-induced changes in adenosine receptor mRNA expression may result in similar changes in receptor density and, thus, receptor function. The present study demonstrates that changes in gastric adenosine receptor gene expression can occur with corresponding changes in adenosine receptor function. We have previously suggested that high concentrations of CPA (Ն1 M) may stimulate SLI release through the nonspecific activation of A 2A receptors (Yip and Kwok, 2004b) . After 3 days of omeprazole treatment, the stimula- (n Ն5); ૺૺૺ, P Ͻ 0.001 when compared with period 3 using repeated measures ANOVA followed by Dunnett's multiple comparison test. The SLI release during each 5-min period was compared between omeprazole-treated and control rats using the Student's unpaired t test and found to differ significantly during periods 6, 7, and 8; †, P Ͻ 0.05. . Furthermore, in comparison to the A 1 receptors, the relative abundance of the gastric mucosal A 2A receptors was found to be relatively low Yip et al., 2004b) , suggesting the existence of a fairly small A 2A receptor reserve in this region. Thus, changes in A 2A receptor expression may readily alter somatostatin secretion.
Contrary to the A 2A receptor, the A 1 receptor is highly expressed in the gastric mucosa (Yip et al., 2004b) . A 1 receptors are expressed on all G-cells, all corporeal D-cells, and some antral D-cells (Yip et al., 2004b) . Thus, a large A 1 receptor population may be present in the rat gastric mucosa. In the present study, omeprazole treatment reduced A 1 receptor gene expression in the antrum and corporeal mucosa but did not alter A 1 receptor-mediated inhibition of IRG and SLI release. The large reserve of A 1 receptors may prevent decreased A 1 receptor expression from altering gastrin and somatostatin release, thus resulting in a discrepancy between changes in A 1 receptor mRNA levels and A 1 receptor function. However, this discrepancy may also be due to other factors. The present study examined the effect of short-term (1-and 3-day) omeprazole treatment. Although changes in actual receptor expression may require more time to occur, the effect of a longer treatment regimen was not examined. In rats treated with omeprazole for more than 3 days, both G-cell and D-cell density have been shown to be altered (Pawlikowski et al., 1992; Bolkent and Yilmazer, 1997) . Any changes in adenosine receptor mRNA expression may be complicated by the alterations in G-cell and D-cell numbers, Each column represents the mean Ϯ S.E.M.; ૺ, P Ͻ 0.05, and ૺૺૺ, P Ͻ 0.001 when compared with period 3 using repeated measures ANOVA followed by Dunnett's multiple comparison test (n Ն5). The SLI release during each 5-min period was compared between omeprazole-treated and control rats using the Student's unpaired t test. In 1-day treated rats perfused with 0.1 M CPA (A), SLI release did not differ from controls. In 3-day treated rats perfused with 1 M CPA (B), SLI release was found to differ significantly during periods 4 and 5; †, P Ͻ 0.05, and † †, P Ͻ 0.01. since adenosine receptors are present on both these endocrine cell types. The adenosine receptors are also expressed in different regions of the stomach, including the enteric plexi and vasculature. Thus, it is also possible that changes in adenosine receptor mRNA expression may occur in anatomical structures that are not involved in the control of IRG and SLI release. The regulation of adenosine receptor gene expression by post-transcriptional mechanisms, such as changes in the translational rate (Ren and Stiles, 1994; Chu et al., 1996; Lee et al., 1999) , also cannot be ruled out. Thus, the disparity between adenosine receptor mRNA levels and receptor function may result from various factors.
The results of this study suggest that adenosine A 1 and A 2A receptor gene expression may respond to changes in the acid-secretory state of the stomach. Omeprazole treatment inhibited both A 1 and A 2A receptor gene expression in gastric tissues. Although A 1 receptor-mediated inhibition of IRG and SLI release was not altered by omeprazole treatment, A 2A receptor-mediated augmentation of SLI release was attenuated. The omeprazole-induced inhibition of A 2A receptor function corresponds with the reduced level of antral A 2A receptor mRNA. These findings suggest that gastric acidity may modulate the purinergic control of IRG and SLI release through the alteration of adenosine receptor expression. The possible modification of adenosine receptor expression by changes in intraluminal acidity may represent a novel purinergic regulatory feedback mechanism to control gastric acid secretion.
